イスラエルのオンライン相談（腫瘍専門医）専門医 — ページ2

Dr. Beni Boursi is a leading oncologist at Sheba Medical Center. He founded the ECOG-ACRIN Microbiome Working Group. He specializes in treating gastrointestinal cancers using innovative microbial modulation. Dr. Boursi is board certified in internal medicine and medical oncology. He earned his medical degree with highest honors from Tel Aviv University.

• Completed oncology fellowships at the University of Pennsylvania.
• Trained in medical oncology at MD Anderson and Mayo Clinic.
• Developed predictive models for early colorectal and pancreatic cancer diagnosis.
• Published research on microbiome-oncology in the prestigious journal Science.

Dr. Avichai Shimoni is the Director of Bone Marrow Transplantation at Sheba Medical Center. He treats complex blood cancers. He completed a specialized fellowship at the MD Anderson Cancer Center. Dr. Shimoni uses allogeneic and autologous transplants for high-risk patients. He is a professor and Chairman of Hematology at Tel Aviv University.

• Named among Israel’s Best Doctors by Forbes for 2025 and 2026.
• Authored over 250 scientific papers on cellular therapies and transplantation.
• Provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Nir Kleinmann directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is a pioneer in kidney-sparing laser surgery for complex tumors. Forbes and ResultMed named him among Israel’s Best Doctors for 2025 and 2026. Dr. Kleinmann uses a unique dual-laser system to preserve organ function during cancer treatment.

• Completed urological fellowships at Thomas Jefferson University and McMaster University.
• Expert in minimally invasive treatments for UTUC, kidney stones, and prostate cancer.
• Served as a researcher in the OLYMPUS trial for non-surgical chemoablation.
• Fellow of the American Endourology Society with over 60 scientific publications.

Dr. Yaacov Lawrence is the Chair of Radiation Oncology at Sheba Medical Center. He specializes in precision radiation therapy and neuro-oncology. Dr. Lawrence pioneered celiac plexus radiosurgery for pancreatic cancer pain management. He holds the FASTRO designation, one of the highest honors in his specialty.

• Leads the Gastrointestinal Cancer Program at Sheba Medical Center.
• Performs stereotactic radiosurgery for brain tumors and nervous system cancers.
• Authored over 280 scientific publications on personalized radiation protocols.
• Completed radiation oncology fellowship training at Thomas Jefferson University.

Dr. Eytan Aharon Ben-Ami leads the Oncology Division at Sheba Medical Center in Israel. He specialized in sarcoma and bone oncology at the Dana-Farber Cancer Institute. Dr. Ben-Ami founded the Sheba Clinical Research Organization to advance cancer studies. He treats rare bone tumors and soft tissue sarcomas with personalized protocols.

• Heads the Early-Phase Clinical Trials Unit for innovative cancer therapies.
• Authored over 40 scientific publications on molecular mechanisms and early detection.
• Leads Phase I trials in targeted therapy and immunotherapy for rare cancers.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Raanan Berger is the Director of the Cancer Center at Sheba Medical Center. He was listed in Forbes Israel’s “Best Doctors” in 2025. Dr. Berger specializes in genitourinary oncology and radiates complex prostate tumors. He completed a postdoctoral fellowship at the Dana-Farber/Harvard Cancer Institute.

• Heads the clinical research unit focusing on molecular oncology.
• Co-authored over 20 peer-reviewed papers on prostate cancer and BRCA mutations.
• Member of the American Society of Clinical Oncology (ASCO).
• Performs systemic therapy and radiotherapy at a Top-10 globally ranked hospital.

Dr. Hila Magen is a leading Israeli hemato-oncologist at Sheba Medical Center. She heads the Multiple Myeloma and Amyloidosis Unit. Dr. Magen specializes in treating complex plasma cell disorders and high-risk myeloma. She is a principal investigator for innovative point-of-care CAR-T therapy programs. Her work brings advanced immunotherapies into routine clinical care.

• Authored over 100 scientific publications and landmark myeloma studies.
• Completed fellowships at MD Anderson and University of Arkansas for Medical Sciences.
• Performs CAR-T cell therapy and bone marrow transplantations.
• Works at Sheba Medical Center, ranked 7th worldwide in 2026 by Newsweek.

Dr. Jair Bar is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He specializes in treating advanced non-small cell lung cancer using personalized immunotherapy and targeted treatments. Dr. Bar holds a PhD in Molecular Biology and leads a research lab focused on immunotherapy resistance.

• Chair of the Israel Lung Cancer Group.
• Board-certified in both Medical Oncology and Radiotherapy Oncology.
• Treats patients at Sheba Medical Center, a top-10 globally ranked hospital.
• Uses molecular and genetic profiling to create precise cancer treatment plans.

Dr. Iris Kventsel is a pediatric hemato-oncologist and bone marrow transplant specialist at Sheba Medical Center. She treats childhood sarcomas like Ewing sarcoma and osteosarcoma at the Edmond and Lily Safra Children’s Hospital. Dr. Kventsel integrates targeted therapies with cellular treatments for complex childhood cancers. She serves on the academic staff at Tel Aviv University Faculty of Medicine.

• Specializes in bone marrow transplantation and CAR T-cell therapy for pediatric patients.
• Researches genetic cancer predisposition, including Li-Fraumeni syndrome and susceptibility genes.
• Published in major journals on stem cell biology and surgical oncology (HIPEC).
• Works at Sheba Medical Center, ranked among the world’s top 10 hospitals.

Dr. Abraham Avigdor is the Director of the Institute of Hematology at Sheba Medical Center. He is a global authority on lymphoma, CAR-T therapy, and complex blood cancers. Dr. Avigdor founded the Israeli Lymphoma Working Group. He helps lead a clinic ranked 7th worldwide by Newsweek in 2026.

• Authored over 130 scientific publications on hemato-oncology and cellular therapy.
• Pioneered the integration of CAR-T cell therapy for lymphoma and myeloma.
• Leads allogeneic and autologous bone marrow transplantation programs.
• Served as the Chairman of the Israeli Lymphoma Study Group.

教育と上級トレーニング コース

• 1989年 - ヘブライ大学で高等医学教育を受ける;
• 1995年 - ハダッサ大学病院で内科および消化器科の研修を修了する。
• 2001年 - 2002年 - ニューヨークのシナイ医学部肝疾患部門でスコット・フリードマン教授とのインターンシップを行う。

現在、リファート・サファディ教授は肝疾患治療の分野で優れた専門家であり、体細胞移植センターの開発委員会のメンバーで、ハダッサ医療センター肝疾患ユニットの責任者です。教授は複数の国際肝研究協会のメンバーであり、専門分野で多くの論文を執筆しています。サファディ教授は、科学医学ジャーナル「Clinical Science」の編集委員会メンバーです。

リファート・サファディ氏は、多くの科学賞の受賞者です。特に彼は、mRNAを用いた肝線維化の免疫調節過程の研究でハダッサ賞を繰り返し受賞しています。同じ分野での業績により、教授はシャロン・ドンスキー賞およびイスラエル消化器病学と肝臓学協会の賞も受賞しました。